GSK plc
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United …
Drug Manufacturers - General
GB, Brentford [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | -2.04 | 0.87 | 0.88 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | -12.51 | 5.92 | 6.76 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 3.37 | 3.40 | 3.29 | |
| Cash | -21.22 | 1.01 | 1.28 | |
| Capex | 28.32 | -0.14 | -0.19 | |
| Free Cash Flow | -82.87 | 0.09 | 0.54 | |
| Revenue | -8.84 | 1.81 | 1.99 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | 3.85 | 0.74 | 0.71 | |
| Operating Margin | 106.14 | 0.27 | 0.13 | |
| ROA | 201.38 | 0.02 | < 0.005 | |
| ROE | 188.21 | 0.08 | 0.03 | |
| ROIC | 37.37 | 0.05 | 0.04 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of GSK is permitted for members.
5
Growth
The "Growth Entry" for the Focus of GSK is permitted for members.
6
Leverage & Liquidity